Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 2Leukemia 2Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 130Methotrexate 93fludarabine phosphate 74Cytarabine 71Vincristine 66Whole-Body Irradiation 65Mycophenolic Acid 58Dexamethasone 55Tacrolimus 49Peripheral Blood Stem Cell Transplantation 48fludarabine 47Busulfan 46pegaspargase 43Filgrastim 41Etoposide 41Doxorubicin 41Calcium Dobesilate 40Granulocyte Colony-Stimulating Factor 39Rituximab 36Cyclosporine 36Mercaptopurine 35Melphalan 33Prednisone 31merphos 28Clofarabine 26Asparaginase 26Antilymphocyte Serum 25Leucovorin 23Daunorubicin 23Thiotepa 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Precursor Cell Lymphoblastic Leukemia-Lymphoma × epratuzumab × Clear all
NCT00098839 2017-12-12

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Children's Oncology Group

Phase 1/2 Completed
134 enrolled 13 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00945815 2017-11-06

S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

SWOG Cancer Research Network

Phase 2 Completed
35 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00941928 2014-05-22

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 3 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡